2004_CD
SkyePharma_NN
Annual_JJ
Report_NN
75_CD
Reconciliation_NOMZ
to_PIN
US_FPP1
Accounting_GER
Principles_NN
Reconciliation_NOMZ
to_PIN
Accounting_GER
Principles_NN
The_DT
financial_JJ
statements_NOMZ
of_PIN
the_DT
Group_NN
are_VPRT [PASS]
prepared_VBN
in_PIN
accordance_NN
with_PIN
generally_RB
accepted_VBN [PRIV]
accounting_GER
principles_NN
in_PIN
the_DT
UK_NN
UK_NN
GAAP_NN
which_WDT [WHSUB]
differs_VPRT
in_PIN
certain_JJ
respects_NN
from_PIN
those_DEMO
applicable_JJ
in_PIN
the_DT
US_FPP1
US_FPP1
GAAP_NN
._.
The_DT
tables_NN
below_PLACE
summarise_NN
the_DT
material_NN
adjustments_NOMZ
to_PIN
the_DT
loss_NN
and_PHC
shareholders_NN
funds_NN
which_WDT [WHSUB]
would_PRMD
be_VB [PASS]
required_VBN [SUAV]
if_COND
US_FPP1
GAAP_NN
had_VBD [PEAS]
been_VBN [PASS]
applied_VBN
instead_CONJ
of_NULL
UK_NN
GAAP_NN
for_PIN
the_DT
applicable_JJ
years_NN
._.
Year_NN
to_PIN
Year_NN
to_PIN
31_CD
December_NN
2003_CD
31_CD
December_NN
2004_CD
restated_VBN
Notes_NN
000_CD
000_CD
Loss_NN
under_IN
UK_NN
GAAP_NN
24,296_CD
43,223_CD
US_FPP1
GAAP_NN
adjustments_NOMZ
:_:
Purchase_NN
accounting_GER
and_PHC
goodwill_NN
Amortisation_NOMZ
of_PIN
goodwill_NN
and_CC
other_JJ
intangibles_NN
1_CD
3,744_CD
3,664_CD
Depreciation_NOMZ
of_PIN
tangible_JJ
fixed_JJ
assets_NN
1_CD
985_CD
823_CD
Deferred_JJ
taxes_NN
1_CD
54_CD
139_CD
Share-based_JJ
compensation_NOMZ
4_CD
1,006_CD
751_CD
Revenue_NN
recognition_NOMZ
5_CD
13,052_CD
13,386_CD
Sale_NN
of_PIN
royalty_NN
interests_NN
Revenue_NN
recognition_NOMZ
6_CD
1,237_CD
6,126_CD
Interest_NN
expense_NN
6_CD
8,694_CD
9,609_CD
Royalty_NN
payments_NOMZ
expensed_VBD
6_CD
2,977_CD
3,144_CD
Financial_NN
instruments_NOMZ
7_CD
516_CD
146_CD
Investments_NOMZ
8_CD
1,893_CD
Share_NN
of_PIN
loss_NN
in_PIN
associate_JJ
9_CD
3,809_CD
1,554_CD
Expenses_NN
of_PIN
convertible_JJ
bond_NN
exchange_NN
10_CD
1,913_CD
Net_JJ
loss_NN
under_IN
US_FPP1
GAAP_NN
20,767_CD
38,638_CD
Net_JJ
loss_NN
per_PIN
Ordinary_NN
Share_NN
under_IN
US_FPP1
GAAP_NN
pence_NN
3.4_CD
p_NN
6.3_CD
p_NN
31_CD
December_NN
2003_CD
31_CD
December_NN
2004_CD
restated_VBN
Notes_NN
000_CD
000_CD
Shareholders_NN
funds_NN
under_IN
UK_NN
GAAP_NN
63,623_CD
84,870_CD
US_FPP1
GAAP_NN
adjustments_NOMZ
:_:
Purchase_NN
accounting_GER
and_PHC
goodwill_NN
Goodwill_NN
1_CD
89,362_CD
85,226_CD
Other_JJ
intangible_JJ
fixed_JJ
assets_NN
1_CD
3,997_CD
4,378_CD
Tangible_JJ
fixed_JJ
assets_NN
1_CD
6,974_CD
7,946_CD
Deferred_JJ
taxes_NN
1_CD
1,632_CD
1,578_CD
Contingent_JJ
consideration_NOMZ
charged_VBN [WZPAST]
to_PIN
goodwill_NN
reserve_NN
1_CD
22,620_CD
22,620_CD
Shares_NN
issued_VBN
relating_VBG
to_PIN
contingent_JJ
consideration_NOMZ
2_CD
11,310_CD
11,310_CD
Shares_NN
and_PHC
warrants_NN
to_TO
be_VB [PASS]
issued_VBN
,_,
deferred_VBN
shares_NN
and_PHC
shares_NN
issued_VBN
3_CD
11,310_CD
11,310_CD
Share-based_JJ
compensation_NOMZ
4_CD
1,461_CD
Deferred_JJ
revenue_NN
5_CD
411_CD
10,887_CD
Funding_GER
liabilities_NOMZ
6_CD
50,363_CD
51,224_CD
Financial_NN
instruments_NOMZ
7_CD
162_CD
354_CD
Fixed_VBN
asset_NN
investments_NOMZ
8_CD
543_CD
Fixed_VBN
asset_NN
investments_NOMZ
Investments_NOMZ
in_PIN
associates_NN
9_CD
11,107_CD
7,298_CD
Convertible_JJ
debt_NN
10_CD
1,913_CD
Shareholders_NN
funds_NN
under_IN
US_FPP1
GAAP_NN
84,699_CD
94,434_CD
76_CD
SkyePharma_NN
Annual_JJ
Report_NN
2004_CD
Reconciliation_NOMZ
to_PIN
US_FPP1
Accounting_GER
Principles_NN
continued_VBD
Revised_VBN
accounting_GER
for_PIN
ESOTs_NN
and_PHC
employee_NN
share_NN
schemes_NN
in_PIN
2004_CD
3_CD
Deferred_JJ
shares_NN
and_PHC
warrants_NN
to_TO
be_VB [PASS]
issued_VBN
Under_IN
UK_NN
GAAP_NN
,_,
contingent_JJ
Under_IN
UK_NN
GAAP_NN
,_,
the_DT
Group_NN
adopted_VBD
UITF_NN
Abstract_NN
38_CD
:_:
Accounting_GER
for_PIN
ESOP_NN
consideration_NOMZ
on_PIN
the_DT
acquisition_NOMZ
of_PIN
Jago_NN
has_VPRT [PEAS]
been_VBN [PASS]
estimated_VBN [PRIV]
and_CC
trusts_NN
for_PIN
the_DT
2004_CD
financial_JJ
statements_NOMZ
as_IN
explained_VBN [PUBV]
in_PIN
note_NN
1_CD
:_:
Accounting_GER
recognized_VBD [PRIV]
within_PIN
shareholders_NN
funds_NN
as_IN
deferred_JJ
shares_NN
._.
As_CONJ
a_NULL
result_NULL
,_,
shares_NN
in_PIN
SkyePharma_NN
PLC_NN
held_VBN [PRIV] [WZPAST]
by_PIN
the_DT
Groups_NN
employee_NN
were_VBD [PASS]
recorded_VBN
using_VBG
the_DT
market_NN
price_NN
at_PIN
the_DT
date_NN
of_PIN
issuance_NN
of_PIN
deferred_JJ
share_NN
ownership_NN
trusts_NN
ESOTs_NN
have_VPRT [PEAS]
been_VBN [PASS]
reclassified_VBN
from_PIN
fixed_VBN
asset_NN
shares_NN
._.
Under_IN
US_FPP1
GAAP_NN
contingent_JJ
consideration_NOMZ
has_VPRT [PEAS]
not_XX0
been_VBN [PASS]
recognized_VBN [PRIV]
._.
investments_NOMZ
and_CC
are_VPRT [SPAU] [PASS]
now_TIME
treated_VBN
as_IN
a_DT
deduction_NOMZ
from_PIN
shareholders_NN
funds_NN
until_IN
such_JJ
time_NN
as_IN
the_DT
shares_NN
in_PIN
the_DT
trust_NN
vest_NN
unconditionally_RB
in_PIN
employees_NN
._.
In_PIN
4_CD
Share-based_JJ
compensation_NOMZ
Under_IN
UK_NN
GAAP_NN
no_SYNE
expense_NN
for_PIN
share_NN
addition_NOMZ
,_,
revisions_NN
to_PIN
UITF_NN
Abstract_NN
17_CD
:_:
Employee_NN
share_NN
schemes_NN
have_VPRT [PEAS]
changed_VBN
options_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
recognized_VBN [PRIV]
as_IN
the_DT
exercise_NN
price_NN
equals_VPRT
the_DT
market_NN
the_DT
basis_NN
on_PIN
which_WDT [PIRE]
the_DT
costs_NN
of_PIN
employee_NN
share_NN
schemes_NN
are_VPRT [PASS]
charged_VBN
to_PIN
the_DT
price_NN
at_PIN
the_DT
date_NN
of_PIN
grant_NN
._.
Under_IN
UK_NN
GAAP_NN
the_DT
prior_JJ
year_NN
comparatives_NN
have_VPRT [PEAS]
been_VBN [PASS]
restated_VBN
for_PIN
the_DT
adoption_NOMZ
of_PIN
UITF_NN
38_CD
,_,
the_DT
revisions_NN
to_PIN
UITF_NN
I7_NN
were_VBD
not_XX0
material_NN
._.
Under_IN
US_FPP1
GAAP_NN
,_,
the_DT
Group_NN
applies_VPRT
APB_NN
25_CD
and_CC
a_DT
compensation_NOMZ
expense_NN
has_VPRT [PEAS]
been_VBN [PASS]
recognized_VBN [PRIV]
for_PIN
performance-based_JJ
compensation_NOMZ
plans_NN
Under_IN
US_FPP1
GAAP_NN
,_,
own_JJ
shares_NN
held_VBN [PRIV] [WZPAST]
are_VPRT [PASS]
shown_VBN [PRIV]
as_IN
a_DT
deduction_NOMZ
from_PIN
variable_JJ
plans_NN
where_RB
it_PIT
is_VPRT [BEMA]
probable_PRED
that_THAC
the_DT
performance_NN
criteria_NN
will_PRMD
be_VB
shareholders_NN
funds_NN
._.
The_DT
change_NN
in_PIN
UK_NN
GAAP_NN
as_IN
described_VBN
above_PLACE
eliminates_VPRT
met_VBN
and_CC
the_DT
options_NOMZ
exercised_VBN [WZPAST]
prior_RB
to_PIN
the_DT
expiration_NOMZ
of_PIN
the_DT
options_NOMZ
issued_VBD
the_DT
material_NN
GAAP_NN
difference_NN
in_PIN
the_DT
way_NN
that_TOBJ
the_DT
ESOT_NN
is_VPRT [PASS]
accounted_VBN
for_PIN
under_IN
these_DEMO
plans_NN
._.
No_SYNE
compensation_NOMZ
expense_NN
has_VPRT [PEAS]
been_VBN [PASS]
recognized_VBN [PRIV]
for_PIN
between_PIN
UK_NN
and_PHC
US_FPP1
GAAP_NN
._.
The_DT
summary_NN
of_PIN
adjustments_NOMZ
between_PIN
UK_NN
and_CC
those_DEMO
plans_NN
that_TSUB
are_VPRT [PASS]
considered_VBN [PRIV]
fixed_VBN
options_NOMZ
plans_NN
and_ANDC
where_RB
the_DT
options_NOMZ
US_FPP1
GAAP_NN
has_VPRT [PEAS]
been_VBN [PASS]
restated_VBN
to_TO
reflect_VB [PRIV]
the_DT
restated_VBN
UK_NN
GAAP_NN
figures_NN
._.
granted_VBN [SUAV]
under_IN
the_DT
plans_NN
are_VPRT [PASS]
granted_VBN [SUAV]
at_PIN
a_DT
price_NN
that_TSUB
equals_VPRT
the_DT
market_NN
price_NN
at_PIN
the_DT
date_NN
of_PIN
grant_NN
._.
1_CD
Business_NOMZ
combinations_NOMZ
Under_IN
both_DT
UK_NN
and_PHC
US_FPP1
GAAP_NN
acquisitions_NOMZ
of_PIN
subsidiary_NN
undertakings_GER
have_VPRT [PEAS]
been_VBN [PASS]
accounted_VBN
for_PIN
as_IN
acquisitions_NOMZ
and_CC
the_DT
5_CD
Revenue_NN
recognition_NOMZ
Under_IN
UK_NN
GAAP_NN
revenue_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
when_RB [WHCL]
it_PIT
purchase_VB
consideration_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
allocated_VBN
to_PIN
the_DT
net_JJ
assets_NN
acquired_VBN [WZPAST]
at_PIN
is_VPRT [PASS]
earned_VBN
and_CC
non-refundable_JJ
and_CC
to_PIN
the_DT
extent_NN
that_DEMO
there_EX
are_VPRT
no_SYNE
future_JJ
their_TPP3
fair_JJ
value_NN
at_PIN
the_DT
date_NN
of_PIN
acquisition_NOMZ
,_,
with_PIN
the_DT
difference_NN
treated_VBN
as_IN
obligations_NOMZ
pursuant_JJ
to_PIN
the_DT
revenue_NN
,_,
in_PIN
accordance_NN
with_PIN
the_DT
contract_NN
goodwill_NN
._.
In_PIN
the_DT
allocation_NOMZ
of_PIN
consideration_NOMZ
,_,
and_ANDC
the_DT
treatment_NOMZ
of_PIN
deferred_VBN
terms_NN
._.
Refundable_JJ
revenue_NN
is_VPRT [PASS]
treated_VBN
as_IN
deferred_VBN
until_IN
such_EMPH
a_NULL
time_NN
as_IN
consideration_NOMZ
,_,
certain_JJ
differences_NN
between_PIN
UK_NN
and_PHC
US_FPP1
GAAP_NN
arise_VB
as_RB
set_VBN
it_PIT
is_VPRT
no_RB
longer_RB
refundable_JJ
._.
Under_IN
US_FPP1
GAAP_NN
,_,
SAB_NN
104_CD
requires_VPRT [SUAV]
deferral_JJ
out_PIN
below_PLACE
._.
and_ANDC
amortisation_NOMZ
of_PIN
up-front_JJ
licensing_GER
fees_NN
where_RB
there_EX
is_VPRT
a_DT
continuing_VBG
involvement_NOMZ
with_PIN
the_DT
licensed_JJ
asset_NN
through_PIN
the_DT
provision_NN
of_PIN
research_NN
Under_IN
UK_NN
GAAP_NN
,_,
prior_RB
to_PIN
the_DT
introduction_NOMZ
of_PIN
FRS10_NN
,_,
goodwill_NN
was_VBD [PASS]
written_VBN [PUBV]
and_CC
development_NOMZ
services_NN
,_,
manufacturing_VBG
services_NN
or_CC
other_JJ
similar_JJ
off_PIN
to_PIN
reserves_NN
and_CC
has_VPRT [PEAS]
not_XX0
been_VBN [PASS]
reinstated_VBN
on_PIN
the_DT
balance_NN
sheet_NN
._.
activities_NOMZ
even_RB
if_COND
the_DT
fee_NN
is_VPRT [BEMA]
non-refundable_PRED
._.
As_CONJ
a_NULL
result_NULL
,_,
under_IN
US_FPP1
GAAP_NN
certain_JJ
non-refundable_JJ
up-front_JJ
payments_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
deferred_VBN
over_IN
US_FPP1
GAAP_NN
requires_VPRT [SUAV]
an_DT
allocation_NOMZ
of_PIN
the_DT
purchase_NN
consideration_NOMZ
to_PIN
the_DT
development_NOMZ
period_NN
of_PIN
the_DT
contract_NN
term_NN
on_PIN
certain_JJ
agreements_NOMZ
._.
identifiable_JJ
intangible_JJ
assets_NN
,_,
including_VBG [PRESP]
any_QUAN
resulting_VBG
from_PIN
acquired_VBN
in-process_JJ
research_NN
and_PHC
development_NOMZ
._.
Prior_RB
to_PIN
2002_CD
,_,
goodwill_NN
was_VBD [BEMA]
Deferred_JJ
revenue_NN
reflects_VPRT [PRIV]
the_DT
amount_NN
of_PIN
revenue_NN
not_XX0
currently_RB
eligible_JJ
amortised_VBN
over_IN
its_PIT
useful_JJ
life_NN
._.
Since_OSUB
1_CD
January_NN
2002_CD
goodwill_NN
is_VPRT
no_RB
longer_RB
for_PIN
recognition_NOMZ
under_IN
US_FPP1
GAAP_NN
as_RB
well_RB
as_IN
the_DT
reversal_NN
of_PIN
deferred_JJ
income_NN
amortised_VBN
under_IN
US_FPP1
GAAP_NN
,_,
but_CC
instead_CONJ
subject_JJ
to_PIN
annual_JJ
impairment_NOMZ
under_IN
UK_NN
GAAP_NN
related_VBN [WZPAST]
to_PIN
the_DT
sale_NN
of_PIN
royalty_NN
interests_NN
,_,
since_OSUB
this_DEMP
is_VPRT
tests_NN
._.
This_DEMO
results_NN
in_PIN
a_DT
reversal_NN
of_PIN
goodwill_NN
amortisation_NOMZ
charged_VBN
under_IN
recorded_VBN
as_IN
funding_GER
liabilities_NOMZ
under_IN
US_FPP1
GAAP_NN
._.
Intangible_JJ
fixed_JJ
assets_NN
recognized_VBN [PRIV]
under_IN
US_FPP1
GAAP_NN
purchase_NN
accounting_GER
requirements_NOMZ
are_VPRT [PASS]
amortised_VBN
over_IN
their_TPP3
estimated_VBN [PRIV]
revenue_NN
6_CD
Sale_NN
of_PIN
royalty_NN
interests_NN
Under_IN
UK_NN
GAAP_NN
payments_NOMZ
received_VBD
from_PIN
a_DT
earning_VBG
life_NN
._.
Negative_JJ
goodwill_NN
,_,
if_COND
any_QUAN
,_,
is_VPRT [BYPA]
eliminated_VBN
by_PIN
reducing_VBG
the_DT
third_JJ
party_NN
in_PIN
return_NN
for_PIN
the_DT
sale_NN
of_PIN
a_DT
proportion_NOMZ
of_PIN
potential_JJ
future_JJ
royalty_NN
value_NN
of_PIN
all_QUAN
non-current_JJ
assets_NN
acquired_VBN
._.
streams_NN
from_PIN
a_DT
selection_NOMZ
of_PIN
products_NN
,_,
and_ANDC
used_VBD
to_TO
fund_VB
the_DT
internal_JJ
research_NN
and_PHC
development_NOMZ
of_PIN
products_NN
,_,
are_VPRT [PASS]
reflected_VBN [PRIV]
within_PIN
other_JJ
The_NN
Group_NN
effected_VBD
the_DT
acquisition_NOMZ
of_PIN
Jago_NN
and_PHC
Krypton_NN
through_PIN
the_DT
operating_GER
income_NN
when_RB
the_DT
risk_NN
of_PIN
reimbursement_NOMZ
has_VPRT [SPAU] [PEAS]
effectively_RB
been_VBN
exchange_NN
of_PIN
warrants_NN
and_PHC
shares_NN
._.
The_DT
issuance_NN
of_PIN
certain_JJ
shares_NN
is_VPRT [PASS]
transferred_VBN
to_PIN
the_DT
third_JJ
party_NN
._.
Royalties_NN
paid_VBD
to_PIN
third_JJ
parties_NN
are_VPRT [PASS]
treated_VBN
contingent_JJ
upon_PIN
the_DT
occurrence_NN
of_PIN
certain_JJ
future_JJ
events_NN
._.
Under_IN
UK_NN
GAAP_NN
,_,
as_IN
cost_NN
of_PIN
goods_NN
sold_VBN
._.
the_DT
fair_JJ
value_NN
of_PIN
the_DT
contingent_JJ
consideration_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
estimated_VBN [PRIV]
to_TO
determine_VB [SUAV] [PRIV]
the_DT
acquisition_NOMZ
cost_NN
and_CC
the_DT
resulting_VBG
goodwill_NN
has_VPRT [PEAS]
been_VBN
US_FPP1
GAAP_NN
requires_VPRT [SUAV]
such_JJ
payments_NOMZ
to_TO
be_VB [PASS]
recorded_VBN
as_IN
debt_NN
where_RB
there_EX
eliminated_VBN
against_PIN
shareholders_NN
funds_NN
._.
is_VPRT
continuing_VBG
involvement_NOMZ
in_PIN
the_DT
generation_NOMZ
of_PIN
the_DT
cash_NN
flows_VPRT
due_JJ
to_PIN
the_DT
third_JJ
party_NN
._.
The_DT
US_FPP1
GAAP_NN
adjustment_NOMZ
for_PIN
the_DT
statement_NOMZ
of_PIN
operations_NOMZ
Under_IN
US_FPP1
GAAP_NN
contingent_JJ
consideration_NOMZ
is_VPRT [PASS]
recognized_VBN [PRIV]
only_DWNT
when_RB
the_DT
includes_VPRT
the_DT
reversal_NN
of_PIN
other_JJ
UK_NN
GAAP_NN
operating_VBG [WZPRES]
income_NN
recorded_VBN
contingency_NN
is_VPRT [PASS]
resolved_VBN [SUAV]
and_CC
consideration_NOMZ
is_VPRT [PASS]
issued_VBN
or_CC
becomes_VPRT
issuable_JJ
._.
from_PIN
the_DT
third_JJ
party_NN
offset_VBN [WZPAST]
by_PIN
recording_VBG
the_DT
interest_NN
charge_NN
for_PIN
the_DT
period_NN
on_PIN
the_DT
outstanding_JJ
US_FPP1
GAAP_NN
debt_NN
balance_NN
._.
Repayments_NOMZ
made_VBD
to_PIN
third_JJ
Under_IN
US_FPP1
GAAP_NN
deferred_VBD
taxation_NOMZ
associated_VBN [WZPAST]
with_PIN
certain_JJ
purchase_NN
parties_NN
in_PIN
the_DT
form_NN
of_PIN
royalty_NN
payments_NOMZ
that_TSUB
are_VPRT [PASS]
expensed_VBN
under_IN
UK_NN
GAAP_NN
accounting_GER
differences_NN
has_VPRT [SPAU] [PEAS]
also_RB
been_VBN [PASS]
recorded_VBN
._.
are_VPRT [PASS]
reversed_VBN
under_IN
US_FPP1
GAAP_NN
and_CC
are_VPRT [PASS]
treated_VBN
as_IN
repayment_NOMZ
of_PIN
debt_NN
._.
2_CD
Shares_NN
issued_VBN
related_VBN
to_PIN
contingent_JJ
consideration_NOMZ
In_PIN
April_NN
2002_CD
the_DT
In_PIN
order_NN
to_TO
record_VB
this_DEMO
funding_GER
liability_NOMZ
in_PIN
accordance_NN
with_PIN
US_FPP1
GAAP_NN
,_,
Deferred_NN
A_NN
Shares_NN
were_VBD [SPAU] [PASS]
automatically_RB
converted_VBN
into_PIN
Ordinary_NN
Shares_NN
on_PIN
royalty_NN
cash_NN
flows_NN
are_VPRT [SPAU] [PASS]
periodically_RB
reassessed_VBN
and_PHC
recorded_VBN
within_PIN
the_DT
the_DT
first_JJ
commercial_JJ
launch_NN
of_PIN
Paxil_NN
CR_NN
._.
Under_IN
US_FPP1
GAAP_NN
,_,
these_DEMO
shares_NN
operating_VBG [WZPRES]
subsidiary_NN
that_TSUB
ultimately_RB
received_VBN
the_DT
funds_NN
._.
Under_IN
FAS_NN
52_CD
:_:
were_VBD [PASS]
recorded_VBN
at_PIN
the_DT
market_NN
price_NN
at_PIN
the_DT
date_NN
of_PIN
conversion_NN
._.
Foreign_JJ
currency_NN
translation_NOMZ
,_,
movements_NOMZ
in_PIN
currency_NN
rates_NN
related_VBN [WZPAST]
to_PIN
monetary_JJ
liabilities_NOMZ
are_VPRT [PASS]
expensed_VBN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
and_PHC
translation_NOMZ
differences_NN
upon_PIN
consolidation_NOMZ
are_VPRT [PASS]
recorded_VBN
in_PIN
equity_NOMZ
._.
2004_CD
SkyePharma_NN
Annual_JJ
Report_NN
77_CD
7_CD
Financial_NN
instruments_NOMZ
Under_IN
UK_NN
GAAP_NN
,_,
periodic_JJ
gains_NN
and_CC
loses_VPRT
on_PIN
US_FPP1
GAAP_NN
developments_NOMZ
interest_NN
and_CC
foreign_JJ
currency_NN
derivatives_NN
are_VPRT [PASS]
not_XX0
recognized_VBN [PRIV]
until_IN
the_DT
In_PIN
December_NN
2004_CD
,_,
the_DT
FASB_NN
issued_VBD
Statement_NOMZ
of_PIN
Financial_NN
Accounting_GER
operational_JJ
transactions_NOMZ
to_PIN
which_WDT [PIRE]
they_TPP3
are_VPRT [PASS]
linked_VBN
occur_VPRT
._.
Under_IN
US_FPP1
GAAP_NN
,_,
Standards_NN
No._NN
._.
123R_CD
SFAS_NN
123R_NN
:_:
Share-Based_NN
Payment_NOMZ
which_WDT [WHSUB]
revises_VPRT
SFAS_NN
the_DT
Group_NN
records_NN
all_QUAN
derivative_JJ
instruments_NOMZ
on_PIN
the_DT
balance_NN
sheet_NN
at_PIN
fair_JJ
123_CD
and_CC
supersedes_VPRT
APB_NN
25_CD
._.
SFAS_NN
123R_NN
requires_VPRT [SUAV]
that_THVC
the_DT
cost_NN
of_PIN
all_QUAN
sharevalue_NN
with_PIN
changes_NN
in_PIN
fair_JJ
values_NN
recorded_VBN [WZPAST]
in_PIN
earnings_GER
._.
In_CONJ
addition_NULL
,_,
if_COND
based_VBN
payment_NOMZ
transactions_NOMZ
be_VB [PASS]
recognized_VBN [PRIV]
in_PIN
the_DT
financial_JJ
statements_NOMZ
._.
SFAS_NN
embedded_VBD
derivatives_NN
are_VPRT [PASS]
identified_VBN
,_,
they_TPP3
are_VPRT [PASS]
recorded_VBN
separately_RB
from_PIN
123R_NN
also_RB
establishes_VPRT [PRIV]
fair_JJ
value_NN
as_IN
the_DT
measurement_NOMZ
method_NN
in_PIN
accounting_VBG
their_TPP3
host_NN
contracts_NN
at_PIN
fair_JJ
value_NN
,_,
with_PIN
changes_NN
in_PIN
fair_JJ
value_NN
recognized_VBN [PRIV] [WZPAST]
in_PIN
for_PIN
share-based_JJ
payments_NOMZ
to_PIN
employees_NN
._.
FAS_NN
123R_NN
is_VPRT
to_TO
be_VB [PASS]
applied_VBN
in_PIN
reporting_VBG [PUBV]
current_JJ
earnings_GER
._.
The_DT
Group_NN
is_VPRT
assessing_VBG
the_DT
impact_NN
of_PIN
adoption_NOMZ
of_PIN
this_DEMO
standard_NN
._.
8_CD
Fixed_VBN
asset_NN
investments_NOMZ
Under_IN
UK_NN
GAAP_NN
fixed_JJ
asset_NN
investments_NOMZ
are_VPRT [PASS]
stated_VBN [PUBV]
at_PIN
the_DT
lower_JJ
of_PIN
cost_NN
and_CC
net_JJ
realisable_JJ
value_NN
._.
In_PIN
September_NN
2004_CD
,_,
the_DT
Emerging_VBG
Issues_NN
Task_NN
Force_NN
EITF_NN
reached_VBD
a_DT
consensus_NN
on_PIN
EITF_NN
Issue_NN
No._NN
._.
02-14_CD
:_:
Whether_IN
an_DT
Investor_NN
Should_NEMD
Apply_VB
the_DT
Under_IN
US_FPP1
GAAP_NN
,_,
securities_NOMZ
which_WDT [WHSUB]
are_VPRT [PASS]
determined_VBN [SUAV] [PRIV]
to_TO
be_VB [BEMA]
available-for-sale_JJ
Equity_NOMZ
Method_NN
of_PIN
Accounting_GER
to_PIN
Investments_NOMZ
Other_JJ
Than_PIN
Common_NN
Stock_NN
,_,
are_VPRT [PASS]
stated_VBN [PUBV]
at_PIN
fair_JJ
value_NN
and_CC
any_QUAN
unrealised_JJ
gains_NN
or_CC
losses_NN
are_VPRT [PASS]
included_VBN
as_IN
in_PIN
which_WDT [PIRE]
the_DT
Task_NN
Force_NN
reached_VBD
the_DT
consensus_NN
that_TOBJ
an_DT
investor_NN
that_TSUB
has_VPRT
the_DT
a_DT
separate_JJ
component_NN
of_PIN
shareholders_NN
funds_NN
._.
ability_NOMZ
to_TO
exercise_VB
significant_JJ
influence_NN
over_IN
the_DT
operating_GER
and_CC
financial_JJ
policies_NN
of_PIN
the_DT
investee_NN
should_NEMD
apply_VB
the_DT
equity_NOMZ
method_NN
of_PIN
accounting_GER
when_RB
it_PIT
has_VPRT
an_DT
9_CD
Fixed_VBN
asset_NN
investments_NOMZ
Investments_NOMZ
in_PIN
associates_NN
Under_IN
UK_NN
GAAP_NN
investment_NOMZ
in_PIN
common_JJ
stock_NN
and_CC
or_CC
an_DT
investment_NOMZ
that_DEMP
is_VPRT [BEMA]
in-substance_PRED
the_DT
company_NN
has_VPRT [PEAS]
accounted_VBN
for_PIN
its_PIT
investment_NOMZ
in_PIN
Astralis_NN
as_IN
an_DT
associated_VBN
common_JJ
stock_NN
._.
The_DT
consensus_NN
of_PIN
this_DEMO
EITF_NN
is_VPRT
to_TO
be_VB [PASS]
applied_VBN
in_PIN
reporting_GER
periods_NN
undertaking_VBG [WZPRES]
from_PIN
December_NN
2004_CD
,_,
when_RB
it_PIT
gained_VBD
significant_JJ
influence_NN
,_,
beginning_VBG
after_IN
15_CD
September_NN
2004_CD
._.
We_FPP1
do_VPRT
not_XX0
believe_VB [PRIV]
the_DT
adoption_NOMZ
of_PIN
this_DEMO
as_IN
described_VBN
in_PIN
note_NN
12_CD
:_:
Fixed_VBN
Asset_NN
Investments_NOMZ
._.
standard_NN
will_PRMD
have_VB
a_DT
material_NN
impact_NN
on_PIN
our_FPP1
financial_JJ
position_NOMZ
,_,
results_NN
of_PIN
operations_NOMZ
or_CC
cash_NN
flows_NN
._.
Under_IN
US_FPP1
GAAP_NN
,_,
the_DT
ability_NOMZ
to_TO
exercise_VB
significant_JJ
influence_NN
results_NN
in_PIN
a_DT
change_NN
in_PIN
classification_NOMZ
from_PIN
an_DT
available_JJ
for_PIN
sale_NN
investment_NOMZ
to_PIN
an_DT
In_PIN
March_NN
2004_CD
,_,
the_DT
EITF_NN
reached_VBD
a_DT
consensus_NN
on_PIN
EITF_NN
Issue_NN
No._NN
._.
03-1_CD
:_:
The_DT
equity_NOMZ
method_NN
investment_NOMZ
under_IN
APB_NN
18_CD
:_:
Equity_NOMZ
method_NN
of_PIN
accounting_GER
for_PIN
Meaning_GER
of_PIN
Other-Than-Temporary_NN
Impairment_NOMZ
and_CC
Its_PIT
Application_NOMZ
to_PIN
Certain_NN
investments_NOMZ
in_PIN
common_JJ
stock_NN
._.
On_PIN
initial_JJ
application_NOMZ
of_PIN
the_DT
equity_NOMZ
method_NN
,_,
Investments_NOMZ
EITF_NN
03-1_CD
._.
The_DT
guidance_NN
prescribed_VBN
a_DT
three-step_JJ
model_NN
for_PIN
under_IN
US_FPP1
GAAP_NN
,_,
the_DT
Group_NN
must_NEMD [SPAU]
retroactively_RB
restate_VB
the_DT
investment_NOMZ
,_,
determining_VBG [SUAV] [PRIV] [PRESP]
whether_IN [WHCL]
an_DT
investment_NOMZ
is_VPRT [PASS]
impaired_VBN
and_CC
results_NN
of_PIN
operations_NOMZ
and_CC
retained_VBN
earnings_GER
in_PIN
a_DT
manner_NN
consistent_JJ
with_PIN
requires_VPRT [SUAV]
disclosure_NN
for_PIN
unrealised_JJ
losses_NN
on_PIN
investments_NOMZ
._.
In_PIN
September_NN
2004_CD
,_,
the_DT
accounting_GER
for_PIN
a_DT
step_NN
acquisition_NOMZ
of_PIN
a_DT
subsidiary_NN
which_WDT [WHSUB]
is_VPRT [BEMA]
different_PRED
the_DT
FASB_NN
issued_VBD
FASB_NN
Staff_NN
Position_NOMZ
EITF_NN
03-1-1_CD
:_:
Effective_NN
Date_NN
of_PIN
Paragraphs_NN
to_PIN
the_DT
treatment_NOMZ
under_IN
UK_NN
GAAP_NN
._.
This_DEMP
constitutes_VPRT
a_DT
change_NN
in_PIN
accounting_GER
10-20_CD
of_PIN
EITF_NN
Issue_NN
No._NN
._.
FSP_NN
EITF_NN
03-1-1_CD
delays_NN
the_DT
principle_NN
._.
In_PIN
consideration_NOMZ
of_PIN
this_DEMO
change_NN
in_PIN
status_NN
,_,
the_DT
investment_NOMZ
in_PIN
effective_JJ
date_NN
for_PIN
the_DT
measurement_NOMZ
and_PHC
recognition_NOMZ
guidance_NN
contained_VBN [WZPAST]
in_PIN
Astralis_NN
has_VPRT [PEAS]
been_VBN [PASS]
adjusted_VBN
for_PIN
increases_NN
in_PIN
ownership_NN
interest_NN
according_VBG [WZPRES]
paragraphs_NN
10-20_CD
of_PIN
EITF_NN
03-1_CD
._.
The_DT
disclosure_NN
requirements_NOMZ
of_PIN
EITF_NN
03-1_CD
to_PIN
the_DT
accounting_GER
for_PIN
a_DT
step_NN
acquisition_NOMZ
and_CC
reduced_VBN
to_TO
recognize_VB [PRIV]
the_DT
remain_VPRT
effective_JJ
for_PIN
fiscal_JJ
years_NN
ending_VBG [WZPRES]
after_IN
15_CD
June_NN
2004_CD
._.
No_SYNE
effective_JJ
date_NN
Groups_NN
share_NN
of_PIN
the_DT
losses_NN
of_PIN
Astralis_NN
after_IN
the_DT
date_NN
of_PIN
initial_JJ
acquisition_NOMZ
._.
for_PIN
the_DT
measurement_NOMZ
and_PHC
recognition_NOMZ
guidance_NN
has_VPRT [PEAS]
been_VBN [PASS]
established_VBN [PRIV]
in_PIN
This_DEMO
change_NN
in_PIN
accounting_GER
principle_NN
results_NN
in_PIN
a_DT
decrease_NN
to_PIN
the_DT
carrying_VBG
FSP_NN
EITF_NN
03-1-1_CD
._.
During_PIN
the_DT
period_NN
of_PIN
delay_NN
,_,
FSP_NN
EITF_NN
03-1-1_CD
states_NN
that_DEMO
value_NN
of_PIN
Astralis_NN
by_PIN
6.9_CD
million_CD
at_PIN
31_CD
December_NN
2003_CD
and_CC
an_DT
increase_NN
companies_NN
should_NEMD
continue_VB
to_TO
apply_VB
current_JJ
guidance_NN
to_TO
determine_VB [SUAV] [PRIV]
if_COND
an_DT
in_PIN
the_DT
losses_NN
recorded_VBD
as_CONJ
a_NULL
result_NULL
of_PIN
the_DT
equity_NOMZ
method_NN
of_PIN
1.6_CD
million_CD
impairment_NOMZ
is_VPRT [BEMA]
other-than-temporary_PRED
._.
The_DT
adoption_NOMZ
of_PIN
EITF_NN
03-1_CD
,_,
excluding_VBG [PRESP]
for_PIN
the_DT
year_NN
ended_VBD
2003_CD
._.
paragraphs_NN
10-20_CD
,_,
did_VBD
not_XX0
impact_VB
the_DT
Groups_NN
consolidated_JJ
position_NOMZ
,_,
results_NN
of_PIN
operations_NOMZ
or_CC
cash_NN
flows_NN
._.
The_DT
Group_NN
will_PRMD
assess_VB
the_DT
impact_NN
of_PIN
paragraphs_NN
10_CD
Convertible_JJ
debt_NN
Under_IN
UK_NN
GAAP_NN
the_DT
Group_NN
exchanged_VBD
49.6_CD
million_CD
10-20_CD
of_PIN
EITF_NN
03-1_CD
once_TIME
the_DT
guidance_NN
has_VPRT [PEAS]
been_VBN [PASS]
finalized_VBN
._.
of_PIN
its_PIT
convertible_JJ
debt_NN
due_JJ
2005_CD
for_PIN
convertible_JJ
debt_NN
in_PIN
the_DT
same_JJ
amount_NN
due_JJ
2024_CD
._.
The_DT
Group_NN
wrote-off_PIN
the_DT
issue_NN
costs_VPRT
associated_VBN
with_PIN
the_DT
original_JJ
convertible_JJ
debt_NN
due_JJ
2005_CD
as_IN
an_DT
exceptional_JJ
item_NN
in_PIN
2004_CD
._.
Under_IN
US_FPP1
GAAP_NN
the_DT
exchange_NN
is_VPRT [PASS]
treated_VBN
as_IN
a_DT
modification_NOMZ
according_VBG [WZPRES]
to_PIN
EITF_NN
96-19_CD
and_ANDC
therefore_CONJ
costs_NN
associated_VBN [WZPAST]
with_PIN
the_DT
exchange_NN
of_PIN
debt_NN
of_PIN
49.6_CD
million_CD
due_JJ
2024_CD
have_VPRT [PEAS]
been_VBN [PASS]
expensed_VBN
._.
Company_NN
Information_NOMZ
and_PHC
Advisors_NN
Registered_NN
and_PHC
Head_NN
Office_NN
Bankers_NN
105_CD
Piccadilly_NN
National_NN
Westminster_NN
Bank_NN
plc_NN
London_NN
W1J_NN
7NJ_NN
Bishopsgate_NN
Business_NOMZ
Centre_NN
Telephone_NN
:_:
020 7491 1777_CD
PO_NN
Box_NN
34_CD
Fax_NN
:_:
020 7491 3338_CD
15_CD
Bishopsgate_NN
Registered_NN
No_NN
:_:
107582_CD
London_NN
EC2P_NN
2AP_NN
Secretary_NN
:_:
Douglas_NN
Parkhill_NN
Registrars_NN
Auditors_NN
Capita_NN
Registrars_NN
LLP_NN
The_DT
Registry_NN
Chartered_NN
Accountants_NN
34_CD
Beckenham_NN
Road_NN
1_CD
Embankment_NOMZ
Place_NN
Beckenham_NN
London_NN
WC2N_NN
6RH_NN
Kent_NN
BR3_NN
4TU_NN
Solicitors_NN
Depositary_NN
UK_NN
The_NN
Bank_NN
of_PIN
New_NN
York_NN
Stringer_NN
Saul_NN
101_CD
Barclay_NN
Street_NN
17_CD
Hanover_NN
Square_NN
New_NN
York_NN
London_NN
W1S_NN
1HU_NN
NY_NN
10286_CD
USA_NN
US_FPP1
Sullivan_NN
&_CC
Cromwell_NN
1_CD
New_NN
Fetter_NN
Lane_NN
London_NN
EC4A_NN
1AN_NN
Corporate_NN
Broker_NN
and_PHC
Financial_NN
Adviser_NN
Credit_NN
Suisse_NN
First_NN
Boston_NN
20_CD
Columbus_NN
Courtyard_NN
London_NN
E14_NN
4DA_NN
